Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Major approval obtained for Mylotarg, the first antibody-targeted chemotherapy product

May 19, 2000

No Comments

Mechanism of action of OvaRex clarified

May 16, 2000

No Comments

DSRB review supports continuation of Allovectin-7 trials

May 16, 2000

No Comments

Therion's Prostvac vaccine shows promise in phase I prostate cancer study

May 15, 2000

No Comments

Important drug warning issued for Herceptin

May 12, 2000

No Comments

Patients with ovarian cancer sought for phase III trial

May 11, 2000

No Comments

Multikine shows promising efficacy and safety in phase II trial

May 11, 2000

No Comments

FDA grants fast track status to Biomira's breast cancer vaccine

May 10, 2000

No Comments

Maxamine plus IL-2 improves survival in late-stage malignant melanoma

May 4, 2000

No Comments

Neurocrine Biosciences obtains orphan drug status for glioblastoma therapy

May 2, 2000

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Immuno-oncology
RSS

Major approval obtained for Mylotarg, the first antibody-targeted chemotherapy product

Mechanism of action of OvaRex clarified

DSRB review supports continuation of Allovectin-7 trials

Therion's Prostvac vaccine shows promise in phase I prostate cancer study

Important drug warning issued for Herceptin

Patients with ovarian cancer sought for phase III trial

Multikine shows promising efficacy and safety in phase II trial

FDA grants fast track status to Biomira's breast cancer vaccine

Maxamine plus IL-2 improves survival in late-stage malignant melanoma

Neurocrine Biosciences obtains orphan drug status for glioblastoma therapy

Today's news in brief

Today's news in brief

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

Australia’s Celosia heads toward clinic with gene therapy for ALS

Sangamo stock plunges as Pfizer leaves hemophilia partnership

Immuno-oncology RSS

Immuno-oncology
RSS